Site augmentation provides a transformative approach to clinical trials by eliminating operational bottlenecks and optimizing efficiency.

With increasing trial complexity and resource limitations at research sites, this support model – built after the proven Functional Service Provider (FSP) strategy – provides specialized personnel to support patient recruitment, data management and study coordination.

Research challenges, including staff shortages, high turnover and poor patient enrollment, often delay trials and escalate costs. Nearly 80% of trials fail to meet enrollment targets on time, costing sponsors millions. Instead of opening new sites, site augmentation optimizes existing ones, offering flexible, scalable support customized to trial demands.

In this featured industry article, Marken’s Head of Global DCT Market Development, Robin Marcus, explores how integrating site augmentation strengthens trial productivity and accelerates timelines for sponsors. A trusted augmentation partner brings expertise across patient care, regulatory compliance and technology management, ensuring seamless execution. Strategic collaboration among stakeholders is critical for sustaining this model and expediting patient access to life-changing medicinal products.